SAN DIEGO, Oct. 17, 2017 /PRNewswire/ -- Tocagen Inc.
(Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy
company, today announced that updated data from the company's Phase
1 study of Toca 511 & Toca FC in recurrent high grade glioma
(brain cancer), have been selected for an oral presentation at the
annual International Conference on Molecular Targets and Cancer
Therapeutics of the American Association for Cancer Research
(AACR), the National Cancer Institute, and the European
Organisation for Research and Treatment of Cancer (EORTC), or
AACR-NCI-EORTC, held Oct. 26-30 in
Philadelphia. Clinical data
demonstrating durable responses have been selected for inclusion in
the conference's official press program. Additional updated Phase 1
data and preclinical results, as well as previously disclosed data,
will also be presented.
Details of the AACR-NCI-EORTC presentations are as follows:
Presentation Type: Oral (Abstract: A085; selected for
inclusion in the official press program of AACR-NCI-EORTC.)
Title: Durable responses observed in recurrent high-grade
glioma (rHGG) with Toca 511 and Toca FC treatment
Presenter: Clark Chen, M.D.,
Ph.D., Lyle French Chair in Neurosurgery and head of the
University of Minnesota Medical School
Department of Neurosurgery
Date and Time: Friday, Oct.
27, 12:10 p.m.-12:20 p.m. ET
(Note: Webcast available Nov. 6.)
Presentation Type: Poster (Abstract: A085; selected for
inclusion in the official press program of AACR-NCI-EORTC.)
Title: Durable responses observed in recurrent high-grade
glioma (rHGG) with Toca 511 and Toca FC treatment
Presenter: Asha Das, M.D.,
senior vice president and chief medical officer at Tocagen
Date and Time: Saturday, Oct.
28, 12:30 p.m.-4:00 p.m.
ET
Presentation Type: Poster (Abstract: B010)
Title: Anti-tumor cellular immune response elicited by Toca
511 and Toca FC therapy in preclinical and clinical
studies
Presenter: Tiffany
Montellano, Ph.D., medical science liaison at Tocagen
Date and Time: Sunday, Oct.
29, 12:30 p.m.-4:00 p.m.
ET
About Toca 511 & Toca FC
Tocagen's lead product candidate is a cancer-selective
immunotherapy comprised of an investigational biologic, Toca 511,
and an investigational small molecule, Toca FC, that are designed
to be used together. Toca 511 is an injectable retroviral
replicating vector (RRV) that encodes a prodrug activator enzyme,
cytosine deaminase (CD). CD is derived from yeast, and humans do
not naturally have this gene. Its selective delivery to cancer
cells means that the infected cancer cells selectively carry the CD
gene and produce CD. Toca FC is an investigational orally
administered prodrug, 5-fluorocytosine (5-FC) that is inactive as
an anti-cancer drug. In animal models, Tocagen has shown that 5-FC
is converted into the anticancer drug, 5-FU, at high concentrations
in Toca 511-infected cancer cells that are producing CD. Together,
the Toca 511 & Toca FC combination directly kills cancer cells
and immune-suppressive myeloid cells resulting in activation of the
immune system against the cancer.
About Tocagen
Tocagen is a clinical-stage, cancer-selective gene therapy
company developing first-in-class, broadly applicable product
candidates designed to activate a patient's immune system against
their own cancer. Tocagen is developing its lead investigational
product candidate, Toca 511 & Toca FC, initially for the
treatment of recurrent high grade glioma (HGG), a disease with
significant unmet medical need. The U.S. Food and Drug
Administration (FDA) granted Toca 511 & Toca FC Breakthrough
Therapy Designation for the treatment of recurrent HGG and the
European Medicines Agency (EMA) granted Toca 511 PRIME (PRIority
MEdicines) designation for the treatment of HGG.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
our business plans and objectives, expectations regarding our cash
position, timing and success of our clinical trials and planned
clinical trials, timing of results from our clinical trials, timing
of updates from communications with the FDA and our plans regarding
selection of additional product candidates. Risks that contribute
to the uncertain nature of the forward-looking statements include:
the success, cost and timing of our product candidate development
activities and planned clinical trials; our ability to execute on
our strategy; regulatory developments in the United States and foreign countries; and
our estimates regarding expenses, future revenue and capital
requirements. These and other risks and uncertainties are described
more fully under the caption "Risk Factors" and elsewhere in
Tocagen's filings and reports with the United States Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. Tocagen undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
View original content with
multimedia:http://www.prnewswire.com/news-releases/tocagen-to-present-updated-durable-response-data-from-phase-1-trial-of-toca-511--toca-fc-in-recurrent-brain-cancer-at-the-2017-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-300537609.html
SOURCE Tocagen Inc.